D. E. Shaw & Co. Inc. Purchases 104,892 Shares of Replimune Group, Inc. (NASDAQ:REPL)

D. E. Shaw & Co. Inc. boosted its position in Replimune Group, Inc. (NASDAQ:REPL - Free Report) by 12.1% during the 4th quarter, according to its most recent Form 13F filing with the SEC. The fund owned 972,575 shares of the company's stock after purchasing an additional 104,892 shares during the period. D. E. Shaw & Co. Inc. owned about 1.42% of Replimune Group worth $11,778,000 as of its most recent SEC filing.

Several other institutional investors have also added to or reduced their stakes in REPL. JPMorgan Chase & Co. boosted its stake in shares of Replimune Group by 3.3% in the third quarter. JPMorgan Chase & Co. now owns 249,349 shares of the company's stock worth $2,733,000 after buying an additional 8,074 shares during the last quarter. SG Americas Securities LLC boosted its stake in shares of Replimune Group by 14.7% during the 4th quarter. SG Americas Securities LLC now owns 26,291 shares of the company's stock worth $318,000 after acquiring an additional 3,374 shares in the last quarter. China Universal Asset Management Co. Ltd. grew its holdings in Replimune Group by 24.2% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 16,317 shares of the company's stock valued at $198,000 after purchasing an additional 3,177 shares during the period. Rhumbline Advisers boosted its holdings in Replimune Group by 8.3% in the fourth quarter. Rhumbline Advisers now owns 95,465 shares of the company's stock valued at $1,156,000 after purchasing an additional 7,317 shares during the last quarter. Finally, New York State Common Retirement Fund raised its stake in shares of Replimune Group by 260.8% in the 4th quarter. New York State Common Retirement Fund now owns 43,204 shares of the company's stock worth $523,000 after buying an additional 31,231 shares in the last quarter. Hedge funds and other institutional investors own 92.53% of the company's stock.

Replimune Group Price Performance

NASDAQ:REPL traded down $0.18 during trading hours on Monday, reaching $7.67. 146,604 shares of the company were exchanged, compared to its average volume of 901,255. The business has a 50 day moving average of $8.95 and a 200 day moving average of $11.32. The company has a debt-to-equity ratio of 0.14, a current ratio of 11.43 and a quick ratio of 11.43. Replimune Group, Inc. has a 1-year low of $4.92 and a 1-year high of $17.00. The company has a market capitalization of $590.71 million, a P/E ratio of -2.50 and a beta of 0.68.

Replimune Group (NASDAQ:REPL - Get Free Report) last posted its quarterly earnings results on Wednesday, February 12th. The company reported ($0.79) earnings per share for the quarter, missing analysts' consensus estimates of ($0.70) by ($0.09). Research analysts forecast that Replimune Group, Inc. will post -2.97 EPS for the current year.

Analysts Set New Price Targets

Several equities research analysts have recently commented on the stock. HC Wainwright lifted their price target on shares of Replimune Group from $21.00 to $22.00 and gave the stock a "buy" rating in a research report on Thursday, February 13th. BMO Capital Markets boosted their price target on Replimune Group from $18.00 to $27.00 and gave the company an "outperform" rating in a report on Wednesday, January 22nd. Finally, JPMorgan Chase & Co. lifted their price objective on Replimune Group from $16.00 to $18.00 and gave the company an "overweight" rating in a research report on Wednesday, February 26th. Seven equities research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, Replimune Group has a consensus rating of "Buy" and a consensus price target of $19.43.

About Replimune Group

Replimune Group, Inc, a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma.